MYO10-filopodia support basement membranes at pre-invasive tumor boundaries.

Humans Female Carcinoma, Intraductal, Noninfiltrating / metabolism Pseudopodia / metabolism Breast Neoplasms / pathology Myosins / metabolism Basement Membrane / metabolism Carcinoma, Ductal, Breast / metabolism
DCIS MYO10 basement membrane breast cancer filopodia

Journal

Developmental cell
ISSN: 1878-1551
Titre abrégé: Dev Cell
Pays: United States
ID NLM: 101120028

Informations de publication

Date de publication:
24 10 2022
Historique:
received: 09 03 2022
revised: 26 08 2022
accepted: 28 09 2022
entrez: 25 10 2022
pubmed: 26 10 2022
medline: 28 10 2022
Statut: ppublish

Résumé

Ductal carcinoma in situ (DCIS) is a pre-invasive stage of breast cancer. During invasion, the encapsulating DCIS basement membrane (BM) is compromised, and tumor cells invade the surrounding stroma. The mechanisms that regulate functional epithelial BMs in vivo are poorly understood. Myosin-X (MYO10) is a filopodia-inducing protein associated with metastasis and poor clinical outcome in invasive breast cancer (IBC). We identify elevated MYO10 expression in human DCIS and IBC, and this suggests links with disease progression. MYO10 promotes filopodia formation and cell invasion in vitro and cancer-cell dissemination from progressively invasive human DCIS xenografts. However, MYO10-depleted xenografts are more invasive. These lesions exhibit compromised BMs, poorly defined borders, and increased cancer-cell dispersal and EMT-marker-positive cells. In addition, cancer spheroids are dependent on MYO10-filopodia to generate a near-continuous extracellular matrix boundary. Thus, MYO10 is protective in early-stage breast cancer, correlating with tumor-limiting BMs, and pro-invasive at later stages, facilitating cancer-cell dissemination.

Identifiants

DOI: 10.1016/j.devcel.2022.09.016 PMID: 36283390
pubmed: 36283390
pii: S1534-5807(22)00713-4
doi: 10.1016/j.devcel.2022.09.016
pii:
doi:

Substances chimiques

Myosins EC 3.6.4.1
MYO10 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2350-2364.e7

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests The authors declare no competing interests.

Auteurs

Emilia Peuhu (E)

Institute of Biomedicine and FICAN West Cancer Centre Laboratory, University of Turku, 20520 Turku, Finland; Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland. Electronic address: emilia.peuhu@utu.fi.

Guillaume Jacquemet (G)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland; Åbo Akademi University, Faculty of Science and Engineering, Biosciences, 20520 Turku, Finland; Turku Bioimaging, University of Turku and Åbo Akademi University, 20520 Turku, Finland; InFLAMES Research Flagship Center, Åbo Akademi University, 20520 Turku, Finland. Electronic address: guillaume.jacquemet@abo.fi.

Colinda L G J Scheele (CLGJ)

Division of Molecular Pathology, Oncode Institute-Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands; VIB-KU Leuven Center for Cancer Biology, Department of Oncology, 3000 Leuven, Belgium.

Aleksi Isomursu (A)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Marie-Catherine Laisne (MC)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland; Åbo Akademi University, Faculty of Science and Engineering, Biosciences, 20520 Turku, Finland.

Leena M Koskinen (LM)

Institute of Biomedicine and FICAN West Cancer Centre Laboratory, University of Turku, 20520 Turku, Finland; Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Ilkka Paatero (I)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Kerstin Thol (K)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Maria Georgiadou (M)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Camilo Guzmán (C)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Satu Koskinen (S)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Asta Laiho (A)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland.

Laura L Elo (LL)

Institute of Biomedicine and FICAN West Cancer Centre Laboratory, University of Turku, 20520 Turku, Finland; Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland; InFLAMES Research Flagship Center, University of Turku, 20520 Turku, Finland.

Pia Boström (P)

Department of Pathology, Turku University Hospital, 20520 Turku, Finland; University of Turku, 20520 Turku, Finland.

Pauliina Hartiala (P)

University of Turku, 20520 Turku, Finland; Department of Plastic and General Surgery, Turku University Hospital, 20520 Turku, Finland.

Jacco van Rheenen (J)

Division of Molecular Pathology, Oncode Institute-Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.

Johanna Ivaska (J)

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland; InFLAMES Research Flagship Center, University of Turku, 20520 Turku, Finland; Department of Life Technologies, University of Turku, 20520 Turku, Finland; Western Finnish Cancer Center (FICAN West), University of Turku, FI-20520 Turku, Finland; Foundation for the Finnish Cancer Institute, Tukholmankatu 8, FI-00014 Helsinki, Finland. Electronic address: johanna.ivaska@utu.fi.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › MYO10-filopodia support basement membranes at...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Tumeurs canalaires, lobulaires et médullaires › Carcinome intracanalaire non infiltrant › MYO10-filopodia support basement membranes at...
questionsmedicales.fr › Cellules › Structures cellulaires › Prolongements cytoplasmiques › Pseudopodes › MYO10-filopodia support basement membranes at...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › MYO10-filopodia support basement membranes at...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines du cytosquelette › Protéines des microfilaments › Myosines › MYO10-filopodia support basement membranes at...
questionsmedicales.fr › Tissus › Membranes › Membrane basale › MYO10-filopodia support basement membranes at...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Carcinome canalaire du sein › MYO10-filopodia support basement membranes at...